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• Only 62.6% improved significantly in a cohort of 101 patients at ten years 
• 85% patients were maintained on atypical antipsychotics 
• 55% patients  were on  monotherapy 
• 25% on  two or more antipsychotics, 
including a combinations two 
atypicals ( 18% )
Percentage usage pattern and per day mean dosage in mg were:  
• 23% (295 mg) for clozapine, 
• 7.4% (5.3 mg) for risperidone, 
• 7.6% (17.6) for olanzapine, 
• 10.4 % ( 558 mg) for quetiapine, 
• 23.8% ( 16 mg) for aripiprazole, 
• 5.7% (112 mg) for ziprasidone 
• No significant difference was observed between the patients who showed 
clinical recovery on CGIS amongst different atypical antipsychotics
• Antipsychotics alone do not determine 
good outcome 
• The pathway of care for good outcome 
possibly includes non-drug factors  
• More research is required regarding 
therapeutics determinants of ‘good 
outcome’ in first episode schizophrenia in 
long term for clinical recovery
• First episode hospitalized schizophrenia  
patients (diagnosed according to DSM-IIIR 
criteria) were followed for ten years 
• After ten years, diagnosis was re-
confirmed (using DSM-IV criteria) and 
outcome was assessed
• Outcome was assessed using Clinical 
Global Impression Scale (CGIS)
• CGIS scores were correlated with key 
antipsychotic drug used in preceding 12 
months.
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•Antipsychotic medications form the 
mainstream of treatment in schizophrenia 
• These drugs have several short term as 
well long term advantage
• It is not known if atypical antipsychotics 
have the long-term effect in improving 
outcome and meeting expectations (1,2,3) 
• The present study examined usage and 
association of antipsychotics drugs with 
clinical outcome a long-term naturalistic 
study
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